FDA clears Vivani Medical’s IND for NPM-119 in type 2 diabetes
Vivani Medical, Inc. (Nasdaq: VANI), a pioneer in biopharmaceutical innovations, has reached a pivotal milestone as the U.S. Food and Drug Administration (FDA) has cleared ... Read More
Novo Nordisk acquires Ziylo in $800m deal to advance diabetes treatment
Novo Nordisk, a leading Danish pharmaceutical company, has completed a significant acquisition of Ziylo, a biotechnology spin-out from the University of Bristol, for a deal ... Read More